- United States
- /
- Medical Equipment
- /
- NasdaqGS:NUVA
At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?
NuVasive, Inc. (NASDAQ:NUVA), is not the largest company out there, but it saw significant share price movement during recent months on the NASDAQGS, rising to highs of US$70.78 and falling to the lows of US$56.91. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether NuVasive's current trading price of US$59.79 reflective of the actual value of the mid-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at NuVasive’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.
See our latest analysis for NuVasive
Is NuVasive still cheap?
Good news, investors! NuVasive is still a bargain right now. My valuation model shows that the intrinsic value for the stock is $91.14, but it is currently trading at US$59.79 on the share market, meaning that there is still an opportunity to buy now. What’s more interesting is that, NuVasive’s share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.
Can we expect growth from NuVasive?
Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. NuVasive's earnings over the next few years are expected to double, indicating a very optimistic future ahead. This should lead to stronger cash flows, feeding into a higher share value.
What this means for you:
Are you a shareholder? Since NUVA is currently undervalued, it may be a great time to increase your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.
Are you a potential investor? If you’ve been keeping an eye on NUVA for a while, now might be the time to make a leap. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy NUVA. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed investment decision.
If you'd like to know more about NuVasive as a business, it's important to be aware of any risks it's facing. To that end, you should learn about the 2 warning signs we've spotted with NuVasive (including 1 which doesn't sit too well with us).
If you are no longer interested in NuVasive, you can use our free platform to see our list of over 50 other stocks with a high growth potential.
If you decide to trade NuVasive, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted
Valuation is complex, but we're here to simplify it.
Discover if NuVasive might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisThis article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
About NasdaqGS:NUVA
NuVasive
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery.
Fair value with moderate growth potential.